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a b s t r a c t
This paper reports the development of a novel methodology for the catalytic synthesis of aromatic a-
amino acids, which involves the addition of aryl-organoboron reagents to a,a-ditosylamino esters de-
rived from ethyl glyoxylate, using transition metal catalysts, like Rh and Pd. A library of a-amino esters
(12 with Pd and 8 with Rh), was synthesized with moderate to excellent yields. A highest enantiose-
lectivity of 30% ee was obtained using Hayashi’s ligand. This method was applied to the synthesis of
phenylglycine.
 2013 Elsevier Ltd. All rights reserved.
1. Introduction
Unnatural or non-proteinogenic a-amino acids,1 are ubiquitous
in all living organisms on earth and perhaps the most important
family of carbonyl compounds in biological systems. Due to both
their structural diversity and functional versatility, their scope of
application is huge, covering the ﬁeld of organic and medicinal
chemistry, biology and agrochemical science.2 For instance, nu-
merous therapeutically relevant compounds,3 such as Amoxicillin
(an antibacterial agent) or Enalapril (an antihypertensive agent)
consist of this functionality (see Fig. 1). They can be used as well as
building blocks, in natural product synthesis, or as chiral auxiliaries,
catalysts or ligands.4
Although enzymatic synthesis and chiral resolutions are viable
methods for the production of naturally occurring chiral a-amino
acids,5 they are often not useful for synthesizing non-natural D-
amino acids or amino acids with non-natural side chains. The for-
mation of diastereomeric salts of optically impure amino acid
mixtures,6 followed by chiral resolution is time consuming and
therefore expensive, and thus a need to invest in alternative syn-
thetic routes was deployed. Due to their importance, a variety of
general methods for the synthesis have been described in the
literature,4 amongst these, there is the Strecker synthesis, which
relies on the stereoselective addition of carboxylate synthons
across C]N bonds,4,7 the Knowles Monsanto asymmetric hydro-
genation of a di-dehydro amino acid8 (an efﬁcient industrial pro-
cess to synthesize L-Dopa (see Fig. 1), and the Corey-Link reaction,9
that involves asymmetric addition of hydride to a ketone precursor.
Fig. 1. Examples of important compounds containing the a-amino acid scaffold; L-
Dopa: anti-Parkinson therapeutic agent; Enalapril: antihypertensive therapeutic agent;
L-Canavanive: anti-predatory agent in plants; (S)-Azetidine-2-carboxylic acid: an ana-
logue of proline; Ampicillin and Amoxicillin: antibacterial therapeutic agents; D-Peni-
cillamine: anti-rheumatic therapeutic agent.
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There are, of course, many other routes to chiral a-amino acids,
such as the addition of organic nucleophiles to a-imino esters or
enolates, a methodology that has emerged as one of the most
promising routes to optically enriched a- and b-amino acid de-
rivatives, including b-lactams.10 Sodeoka and co-workers reported
the ﬁrst example of an asymmetric addition of enol silyl ethers to a-
imino esters employing a hydrated Pd(II)-based chiral Lewis acid
system.11 This so called Mannich-type reaction led to optically ac-
tive g-oxo-a-amino esters with modest to high enantioselectivities
(45e95% yield and 53e90% ee). Later on, Kobayashi’s group12 re-
ported an improvement of this methodology using N-acylimine
esters with enol silanes and Cu(II) catalysts to produce N-acylated
amino acids with high yields and high enantioselectivities (77e97%
yield and 90e97% ee) under smooth reaction conditions. Transition
metalephosphane complexes were applied as catalysts by Lectka
group13 for the catalytic asymmetric alkylation of a-imino esters
and N,O-acetals with enol silanes, ketene acetals, alkenes and
allylsilanes. Jorgensen and co-workers14 and Johannsen,15 in-
dependently applied the combination of CuPF6 and (R)-tol-BINAP in
the enantioselective addition of imines to electron-rich aromatic
compounds, affording protected optically active a-aryl a-amino
esters in good to high yields and with high regioselectivity and
enantioselectivity (up to 98% ee). The limitation with this approach
is the restriction to electron-rich aromatic compounds, although
the avoidance of often troublesome enol silyl ethers or silyl ketene
acetals, is the main advantage of this methodology.
Our group is currently engaged in the development of catalytic
reactions for carbonecarbon bond formation using imine sub-
strates and aldehydes, organoboron reagents and transition metal
catalysts.16 We have now developed a new process that affords aryl
a-amino acids via arylation of di-a,a-tosylamino esters with aryl-
boronic acids and transition metal catalysts.
2. Results and discussion
Using the samemethodology applied previously in the synthesis
of imine derivatives,16c the 2,2-bis(4-methylphenylsulfonamido)
acetate ester (2) was synthesized from commercially available ethyl
glyoxylate (1), through the addition of p-toluenesulfonamide, in
toluene, with a catalytic quantity of the Lewis acid BF3$Et2O, by
reﬂuxing in a DeaneStark trap (Scheme 1). The di-a,a-tosylamino
ester (2) has already been prepared by Lectka’s group17 and was
obtained in 20% yield, using equimolar amounts of ethyl glyoxylate
(1) and p-toluenesulfonamide.
Great advances have been made in the ﬁeld of a-arylation of
carbonyl compounds catalyzed by transition metal catalysts.18 The
nucleophilic aromatic substitution of enolates with aryl halides19
and the transition-metal-catalyzed a-arylation of carbonyl com-
pounds20 are the two main methods for efﬁcient construction of
quaternary centres with good enantioselectivity.21 As far as we
know, the arylation of di-a,a-tosylamino estersdwhich are acti-
vated aminal compoundsdhas never been reported in the litera-
ture, so we decided to develop the catalytic arylation of di-
tosylamino ester (2).22 Gratifyingly we observed that the di-
tosylamine ester (2) could be converted to the desired N-tosyl-
amine ester (3a) in 38% yield, when treated with phenylboronic
acid and Pd(OAc)2/bpy (Table 1). Despite the moderate yield, we
were encouraged by the result and proceeded with screening
a plethora of other boronic acids, using the catalytic system de-
scribed above. The advantage of using these arylating agents is that
they are commercially available from a number of suppliers, easy to
handle and have a low toxicity proﬁle.23 The results can be seen in
Table 1. The principle advantage of this method appears to be the
avoidance of imine substrates that undergo facile hydrolysis under
the reaction conditions of their arylation.16c
The yields were moderate to good, showing good tolerance for
the presence of both electron-donating and electron-withdrawing
substituents in the phenyl ring of organoboron reagent. The best
yield was obtained with 1-naphthylboronic acid (Table 1, entry 7).
No signiﬁcant difference was observed using an electron-donating
or an electron-withdrawing group in the organoboron reagent, but
apparently the reaction yield improveddas conﬁrmed from liter-
ature precedent16c,24dwhen an electron-withdrawing group was
present (see Table 1, entries 6 and 8). No very signiﬁcant differences
in the yield were noted when either electron-donating or electron-
withdrawing substituents were present in the ortho, meta or para
positions of the aromatic ring (see Table 1), thus showing good
tolerance for both electronic and steric effects. However in the case
of Rh catalysis (vide infra) this is not the case, and is discussed
below.Wewere also curious to check the scope of this reactionwith
aliphatic boronic acids.25 So, we decided to test three of these
speciﬁc reagents: methylboronic acid, ethylboronic acid and 1-
dodecylboronic acid. Unfortunately the reactions didn’t work,
since only the aminal substrate (2) was recovered. The problem
with these reactions in the context of Pd catalysis was that probably
unnecessary side-reactions, such as homocoupling26 and base-
catalyzed proto-deboration,27 ensued, with the inevitable con-
sumption of the arylboronic acid derivatives. We tried to promote
an asymmetric version of this reaction, using (R,R)-Me-DuPhos
(Fig. 2) as chiral phosphane ligand, and other chiral ligands, such as
oxazoline type and NHC type, applying the conditions previously
developed by us16a but, this was unsuccessful and the yields were
very poor, and thus further investigation was abandoned. At this
point we decided to explore the use of Rh catalysts, for two reasons:
i) to try and improve the yields, and ii) to develop chiral catalysts
Table 1
Screening of arylboronic acid derivatives to afford the a-amino ester derivatives (3)
with Pd catalysts, using the di-tosylamine ester (2) as substrate
Entrya a-Amino ester (3) Yield/%b
1 C6H5 a 38
2 2-Naph b 28
3 2-CH3OC6H4 c 58
4 4-ClC6H4 d 35
5 3-CH3OC6H4 e 56
6 3-AcC6H4 f 61
7 1-Naph g 79
8 4-FC6H4 h 45
9 3-PhCH2OC6H4 i 30
10 3-HOC6H4 j 31
11 3-NH2C6H4 k 37
12 4-CH3OC6H4 l 39
a Reaction conditions: Pd(OAc)2 (5 mol %), bpy (10 mol %), di-a,a-tosylamine ester
(2) (0.3 mmol), ArB(OH)2 (1.0 mmol) and dioxane (2 ml) was used.
b Isolated yields after liquid chromatography.
Scheme 1. Synthesis of N,N-di-p-toluenesulfonylglycine ester (2) using ethyl glyox-
ylate (1) and p-toluenesulfonamide (NH2Ts).
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that would lead to a successful asymmetric version of this reaction.
Thus for this purpose PPh3 and a variety of chiral phosphane li-
gands, were investigated (Fig. 2). Only the best results are high-
lighted in Table 2. We decided to use [Rh(COD)OH]2, as one of the
catalyst precursors, because of its many interesting applications in
the literature.28 Ru was also investigatedd[RuCl2(h6-p-cymene)]2
with (R,R)-Me-DuPhos (6a) and Trost’s ligand (5)dbut the yield
was very poor and the % ee was not determined. In fact, this Rh(I)
catalyst along with (R,R)-DeguPhos (4a) was already applied suc-
cessfully by Ellman’s group in the enantioselective addition of
arylboronic acids to diphenylphosphinoyl imines.28f We also
screened the commercial chiral diene of Hayashi (10) (Fig. 2).29 As
of yet we haven’t established the conﬁguration of the major
enantiomer.
The results were very interesting. What was immediately ob-
served was that better yields than those achieved with Pd were
obtained (e.g., 99%, Table 2, entry 8). We found that generally the
chiral ligands gave better yields than PPh3 (Table 2, entries 1 and 2)
and in fact, when no ligand was present, a yield comparable to that
obtained with PPh3 was obtained (Table 2, entries 3 and 4). The
highest enantioselectivity obtained was 30% ee using Hayashi’s li-
gand (10) and the best with phosphanes was 16% ee recorded with
(4b), but, unfortunately the yields were very low. Although, it
seems that the use of KHF2 as base gave the best yields.
As the enantioselectivities were lower than what we expected,
we decided to establish if there was any racemization taking place.
On performing the reactions with D2O in the reaction medium, it
was established by 1H NMR that there was no incorporation of
deuterium in the a-position. The reaction was also monitored over
a 24 h period, and no deterioration in the reaction enantiose-
lectivity was observed from the 1st to the 24th hour. These ex-
periments show that racemization was not the cause of the low
enantioselectivities. Based on our previous experience,16d it ap-
pears that during the catalytic cycle there is a likely possibility of
exchange of the chiral ligand with the imine substrate, thus elim-
inating or diminishing greatly the asymmetric induction.
HPLC analysis has shown the presence of the imine precursor to
(2) in some of the chromatograms. This seems to support the
conjecture that (2) undergoes elimination of p-tosylsulfonamine
during the catalytic reaction.
We decided on the basis of the good yields achieved with (R,R)-
DeguPhos (4a) and [Rh(COD)OH]2 in this initial screening study
(99% yield, Table 2, entry 8) to access the reaction scope using
a variety of arylboronic acids (Table 3).
Starting with the simple phenylboronic acid, the reaction gave
the expected a-amine ester product (3a) with full conversion (99%
yield, Table 3, entry 1). To test the reaction conditions we decided to
run the same reaction without ligand, in H2O and without additive
(Table 3, entries 2, 3 and 4, respectively). The importance of the
diphosphane ligand on the activity of the active catalyst was clearly
shown (compare entries 1 and 2, Table 3), as well as the importance
of an inorganic additive (KHF2), already used with success in this
reaction type30 (compare entries 1 and 4, Table 3). Since KHF2
under aqueous conditions can react with the organoboronic acids
to generate the more reactive potassium organotriﬂuoroborates30c
we investigated the direct use of this type of reagent on the
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Fig. 2. Some of the chiral ligands that were screened in this study. Note: (6a), (6b), (7),
(8a) and (8b) gave very low enantioselectivities (<5% ee).
Table 2
Transformation of di-tosylamino ester (2) to arylamino ester (3a) using Rh catalysis
O
NHTs
O
(2)
PhB(OH)
2 O
NHTs
O
(3a)
Rh catalyst (3 mol%),
Ligand (3.3 mol%),
55-100
o
C Ph
TsHN +
Entry Rh catalyst Ligand Additive/solvent/temp
(C)
Time
(h)/yield (%)a
eeb
(%)
1 [Rh(COD)OH]2 PPh3 K3PO4/dioxane/70 18(14) n.a.
2 [Rh(COD)OH]2 PPh3 NEt3/toluene/70 18(22) n.a.
3c [Rh(COD)OH]2 None KHF2/dioxane/100 24(13) n.a.
4 [Rh(COD)Cl]2 None MgSO4/dioxane/80 23(22) n.a.
5 [Rh(COD)Cl]2 (4a) MeOH/dioxane/100 16(52) 15
6c [Rh(COD)Cl]2 (4a) KHF2/dioxane/80 17(96) 15
7 [Rh(COD)Cl]2 (4a) KHF2/toluene/55 21(18) 18
8d [Rh(COD)OH]2 (5) KHF2/dioxane/100 24(99) <5
9d [Rh(COD)OH]2 (7) KHF2/dioxane/100 24(94) <5
10d [Rh(COD)OH]2 (9) KHF2/dioxane/100 24(58) 13
11d [Rh(COD)OH]2 (10) KHF2/dioxane/100 24(30) 12
n.a. not applicable.
a Isolated yields after liquid chromatography.
b As determined by HPLC with a chiral column.
c Reaction run with KHF2 3 M (aq solution).
d 0.8 mmol KHF2 was used.
Table 3
Transformation of di-tosylamino ester (2) to arylamino esters (3) using Rh catalysis
Entrya a-Amino ester (3) Yield/%b
1 C6H5 a 99
2c C6H5 a 13
3d C6H5 a 74
4e C6H5 a 34
5 2-Naph b 74
6 2-CH3OC6H4 c 83
7 4-ClC6H4 d 61
8 3-CH3OC6H4 e 0
9 3-AcC6H4 f 0
10 1-Naph g 99
11 4-FC6H4 h 0
12 3-PhCH2OC6H4 i 25
13 3-HOC6H4 j 0
14 3-NH2C6H4 k 17
15 4-CH3OC6H4 l 61
a Reaction conditions: [Rh(COD)OH]2 (1.5 mol %), (R)-DeguPhos (3.3 mol %), di-
tosylamine ester (2) (0.12 mmol), ArB(OH)2 (0.4 mmol), KHF2 (0.8 mmol) and di-
oxane (2 ml) was used.
b Isolated yields after liquid chromatography. All the products were obtained in
racemic form, as determined by HPLC with a chiral column.
c Reaction made without (R,R)-DeguPhos.
d Reaction run with KHF2 3 M (aq solution). Note: the ee values have not been
included due to being too low.
e Reaction runs without additive.
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outcome of the reaction (Table 3, entry 3). The yield decreased from
99% to 34% (Table 3, compare entries 1 and 3). This was un-
doubtedly due to hydrolysis of the activated imine.16a,c
Motivated by the excellent result obtained with this optimized
method (Table 3, entry 1), in order to establish the scope of this
method, we conducted a screening of a range of arylboronic acids.
The yield increased in particular when a naphthylboronic acid was
used (Table 3, entries 5 and 10). Almost all of the organoboron
reagents containing an electron-withdrawing group in the phenyl
ring were inactive (Table 3, entries 8, 9, 11 and 13).
In the case of Rh catalysis, it seems that the catalyst is sensitive
to electronic effects in the aromatic ring of the organoboron re-
agent, as the use of electron-donating substituents in the ortho and
para positions gave good yields, (see Table 3, entries 5, 6, 10 and 15).
But, there was no reaction when strong inductively electron-
withdrawing groups were present in the meta position of the
arylboronic acid (Table 3, entries 8,9 and 13) and when a p-ﬂuoro
group was present (Table 3, entry 11).
No products were obtained when aliphatic boronic acids were
used (methylboronic acid, ethylboronic acid and 1-dodecylboronic
acid). It seems that an aromatic system needs to be present.
Upon ﬁnding the optimal conditions for HPLC analysis, we were
very disappointed to ﬁnd very low enantioselectivities of the order
<5e10% ee for all the compounds synthesized. We then screened
a plethora of commercial diphosphane chiral ligands, to try and
improve the reaction enantioselectivity. Well known ligands,16a,c
such as BINAP (7), DuPhos (6) or Trost-diphosphane (5) (see
Fig. 2) were all screened, but no outstanding improvements were
achieved (a maximum of 15% ee was the best obtained using the
commercial ligand (R,R)-naphthyl Trost-diphosphane (5), Fig. 2).
In order to establish an efﬁcient route to obtaining the free a-
amino acids, the amine activating group needs to be removed. In
fact, this has previously proved to be particularly troublesome with
these systems.31 We thus developed a simple reaction process to
phenylglycine (11) (Scheme 2)dan important motif in the antibi-
otic Ampicillin (see Fig. 1), using an aqueous solution of NaOH in
THF (Scheme 2).32 Obviously, this method of deprotection will
probably lead to the racemic amino acid product when the sub-
strate is optically pure, however, for the purpose of at least
accessing the amino acid product, we successfully demonstrated
the applicability of this method (Scheme 2).
We also discovered that by adding K2CO3 to the reaction me-
dium during the arylation of the di-tosylamino ester (2), the tosyl
group was removed after presumably the formation of the arylated
ester product affording the amine ester product (12), in 72% yield
(Scheme 3). We are currently further investigating the scope of this
procedure.
3. Conclusions
We have reported herein an alternative innovative method for
the synthesis of a-amino acid derivatives using stable 2,2-bis(4-
methylphenylsulfonamido)acetate ester (2). This new methodol-
ogy utilizing arylboronic acids with transition metal catalysts, al-
though not suitable yetddespite promising indicationsdfor the
synthesis of enantioenriched a-aryl amino acids, afforded a diverse
library of a-amine ester products. On-going studies on the mech-
anism are currently underway, as well as studies at optimizing and
improving the reaction enantioselectivity.
4. Experimental section
4.1. General remarks
All the reagentswere obtained fromAldrich, Fluka and Acros. The
commercial diphosphane ligands were obtained from either Strem
Chemicals, or Aldrich, with the exception of the (R,R)-DeguPhos, (R)
and (S)-DioxPhos, which were obtained from ChiraTecnics Lda
(Portugal). The solvents used were dried under current laboratory
techniques.33 1,4-Dioxane was distilled from Na and benzophenone.
All the reagents applied in this work were used as received. All re-
actions with transition metals (Pd, Rh) were conducted under a ni-
trogen atmosphere. The di-tosylamino ester (2) was synthesized
according to literature procedures.16 Column chromatography was
carried out on silica gel (SDS, 70e200 mm). Thin layer chromatogra-
phy (TLC) was carried out on aluminium backed Kieselgel 60 F254
plates (Merck). Plates were visualized either by UV light or with
phosphomolybdic acid in ethanol. The NMR analyses were recorded
on a Bruker Avance instrument (400MHz) usingCDCl3 as solvent and
the signal from the residual CHCl3 used as an internal standard. High
performance liquid chromatographic (HPLC) analysis was performed
on an Agilent 1100 series instrument. The conditions used were:
pmax¼50 bar; ﬂux¼1 ml/min; detector¼wavelength light
(l¼230 nm); eluent¼hexane/isopropanol; column¼Chiralcel OD-H
(0.46 cm25 cm), ﬁtted with a guard column composed of the
same stationary phase. Mass spectra were recorded on either a Wa-
ters-Micromass MaldiTOF or MicroTOF Focus (Bruker Daltonics) by
using the TOF (time-of-light) technique.
4.2. a,a-Ditosylamine ester synthesis
4.2.1. Synthesis of ethyl 2-(tosylimino)acetate substrate (2).17 By
using a DeaneStark trap to facilitate water removal, BF3$Et2O
(1.6103 mol) was added (through a syringe) to a reﬂuxing solu-
tion of ethyl glyoxylate (1) (50% in toluene, 0.1 mol) and p-tolue-
nesulfonamide (0.1 mol) in toluene (200 ml). The mixture was kept
under reﬂux until the theoretical amount of water (0.1 mol) was
collected. The solution was then cooled to room temperature and
a white solid precipitated. The mixture was ﬁltrated and the white
solid washed with toluene. After drying under reduced pressure,
we obtained the desired product in 32% yield. Mp: 178e189 C (mp
lit.: 178e180 C); FTIR (cm1): 1200,1344,1597,1728, 3257. 1H NMR
(400MHz, CDCl3þDMSO-d6) d: 1.00 (t, CH3, 3H), 2.35 (s, CH3Ts, 3H),
3.84e3.89 (q, CH2, 2H), 6.97e6.99 (d, NH, 2H), 7.17e7.19 (d, Ar, 2H),
7.62e7.64 (d, HC]N, 1H) ppm. 13C NMR (100 MHz, CDCl3þDMSO-
d6) d: 13.64, 21.53, 62.51, 63.39, 127.08, 129.41, 137.92, 143.35,
167.43 ppm. MS (ESI-TOF) m/z: 256.07 (Mþ1). HPLC analysis
[Chiralcel OD-H, hexane/2-propanol (95:5), ﬂow rate¼1.0 ml/min,
l¼230 nm]: tR¼11.3 min.
4.3. Catalytic reactions
4.3.1. General procedure for the catalytic addition of boronic acids to
ethyl 2,2-bis(4-methylphenylsulfonamido)acetate (2) using a Pd
Scheme 2. Conversion to the racemic unnatural a-amino acid derivatives. Synthesis of
(rac)-a-phenylglycine.
Scheme 3. One-pot arylationeamine deprotection protocol.
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catalyst22 (Table 1). 1,4-Dioxane (2.0 ml) was added to a round-
bottom ﬂask containing Pd(OAc)2 (5 mol %), bpy ligand
(10 mol %), the organoboron reagent (1.0 mmol) and the 2,2-bis(4-
methylphenylsulfonamido)acetate (2) (0.3 mmol) under nitrogen.
The mixture was stirred at 100 C for 2 days. The crudemixturewas
ﬁltered over Celite using a sintered glass ﬁlter and washed with
CH2Cl2. The organic phase was washed with saturated NH4Cl (aq),
dried with anhydrous MgSO4, ﬁltered and concentrated under re-
duced pressure. Puriﬁcation by column chromatography (SiO2 gel,
hex/AcOEt (5:1)) provided the ﬁnal a-amine ester product (3).
4.3.2. General procedure for the catalytic addition of boronic acid and
derivatives to 2,2-bis(4-methylphenylsulfonamido)acetate (2) using
a Rh catalyst34 (Tables 2 and 3). 1,4-Dioxane (2.0 ml) was added to
a round-bottom ﬂask containing [Rh(COD)OH]2 (1.5 mol %), (R,R)-
DeguPhos (3.3 mol %), 2,2-bis(4-methylphenylsulfonamido)acetate
(2) (0.12 mmol), organoboron reagent (0.4 mmol) and KHF2
(0.8 mmol) under nitrogen. The mixture was stirred at 100 C for 1
day. The solvent was evaporated under reduced pressure and the
crude mixture puriﬁed by column chromatography (SiO2 gel, hex/
AcOEt (5:1)) providing the ﬁnal a-amine ester product (3).
4.3.3. Ethyl 2-(4-methylphenylsulfonamido)-2-phenylacetate
(3a).35 White solid (38% yield). Mp: 88.6e90.4 C. 1H NMR
(400 MHz, CDCl3) d: 1.09 (dd, CH3, 3H), 2.38 (s, CH3Ts, 3H),
3.92e4.08 (m, CH2, 2H), 5.02e5.04 (d, CH, 1H), 5.69e5.71 (m, NH,
1H), 7.18e7.20 (Ar, 2H), 7.22e7.26 (Ar, 5H), 7.62e7.64 (Ar, 2H). 13C
NMR (100 MHz, CDCl3) d: 13.96, 21.61, 59.48, 62.35, 127.10, 127.21,
127.34, 128.63, 128.89, 129.55, 129.58, 129.61, 135.63, 137.09, 138.63,
143.64, 170.19. MS (ESI-TOF) m/z: 334.12 (Mþ1). HPLC [Chiralcel
OD-H column, hexane/2-propanol (95:5), ﬂow rate¼1.0 ml/min,
l¼230 nm]: tR¼20.1 and 21.9 min.
4.3.4. Ethyl 2-(4-methylphenylsulfonamido)-2-(naphthalen-2-yl)ac-
etate (3b).35a,36 Yellow solid (28% yield). Mp: 115.0e116.7 C. 1H
NMR (400 MHz, CDCl3) d: 1.11 (dd, CH3, 3H), 2.26 (s, CH3Ts, 3H),
4.16e4.31 (m, CH2, 2H), 5.22e5.23 (d, CH, 1H), 5.86e5.88 (d, NH,
1H), 7.14e7.15 (Ar, 2H), 7.29e7.34 (Ar, 2H), 7.40e7.44 (Ar, 1H),
7.48e7.49 (Ar, 1H), 7.73e7.77 (Ar, 3H), 7.84e7.86 (Ar, 2H). 13C NMR
(100 MHz, CDCl3) d: 14.08, 22.97, 59.64, 62.34, 109.60, 117.93,
123.67,124.26,126.04,126.46,126.60,127.88,128.57,129.02,129.49,
129.92, 133.43, 134.73, 135.85, 153.60, 173.79. MS (ESI-TOF) m/z:
384.13 (Mþ1). HPLC analysis not carried out.
4.3.5. Ethyl 2-(2-methoxyphenyl)-2-(4-methylphenylsulfonamido)
acetate (3c). White solid (58% yield). 1H NMR (400 MHz, CDCl3) d:
1.09 (dd, CH3, 3H), 2.36 (s, CH3Ts, 3H), 3.92 (s, OCH3, 3H), 4.02e4.24
(m, CH2, 2H), 5.27e5.29 (d, CH, 1H), 5.93e5.95 (d, NH, 1H),
6.91e6.93 (Ar, 2H), 7.02e7.06 (Ar, 2H), 7.44e7.47 (Ar, 2H), 7.85e7.87
(Ar, 2H). 13C NMR (100 MHz, CDCl3) d: 14.06, 21.26, 55.62, 61.72,
70.60, 110.10, 111.23, 120.97, 121.39, 127.20, 127.49, 129.41, 130.01,
130.27, 132.70, 133.11, 136.98, 164.64. MS (ESI-TOF) m/z: 364.13
(Mþ1). HPLC analysis not carried out.
4.3.6. Ethyl 2-(4-chlorophenyl)-2-(4-methylphenylsulfonamido)ace-
tate (3d).35a,36 Yellow oil (35% yield). Mp: 86.8e89.0 C. 1H NMR
(400MHz, CDCl3) d: 1.10 (m, CH3, 3H), 2.39 (s, CH3Ts, 3H), 3.97e4.10
(m, CH2, 2H), 4.99e5.01 (d, CH, 1H), 5.77e5.79 (d, NH, 1H),
6.75e6.77 (Ar, 2H), 7.14e7.22 (Ar, 2H), 7.32e7.38 (Ar, 2H), 7.59e7.61
(Ar, 2H). 13C NMR (100 MHz, CDCl3) d: 14.07, 21.76, 58.73, 62.86,
116.80, 127.20, 127.92, 128.53, 128.98, 129.50, 129,59, 133.94,134.64,
136.86, 143.92, 154.42, 169.75. MS (ESI-TOF) m/z: 368.08 (Mþ1).
HPLC analysis not carried out.
4.3.7. Ethyl 2-(3-methoxyphenyl)-2-(4-methylphenylsulfonamido)
acetate (3e). Yellow oil (56% yield). 1H NMR (400 MHz, CDCl3) d:
1.10 (dd, CH3, 3H), 2.38 (s, CH3Ts, 3H), 3.72 (s, OCH3, 3H), 3.93e4.11
(m, CH2, 2H), 5.02 (d, CH, 1H), 5.72e5.74 (d, NH, 1H), 6.72 (Ar, 1H),
6.77e6.83 (Ar, 2H), 7.14e7.20 (Ar, 3H), 7.61e7.64 (Ar, 2H). 13C NMR
(100 MHz, CDCl3) d: 13.97, 21.60, 55.32, 59.44, 62.38, 112.54, 114.41,
119.56, 127.24, 128.48, 129.42, 129.58, 129.92, 136.83, 137.12, 143.62,
159.90, 170.10. MS (ESI-TOF) m/z: 364.14 (Mþ1). HPLC analysis not
carried out.
4.3.8. Ethyl 2-(3-acetylphenyl)-2-(4-methylphenylsulfonamido)ace-
tate (3f). White solid (61% yield). 1H NMR (400 MHz,
CDCl3þDMSO-d6) d: 0.97 (m, CH3, 3H), 2.40 (s, CH3, 3H), 2.49 (s,
CH3Ts, 3H), 3.81e3.86 (m, CH2, 2H), 5.15e5.20 (s, CH, 1H),
5.90e6.05 (d, NH, 1H), 7.05e7.07 (Ar, 2H), 7.19e7.22 (Ar, 2H),
7.33e7.38 (Ar, 1H), 7.44e7.45 (Ar, 2H), 7.71e7.73 (Ar, 1H). 13C NMR
(100 MHz, CDCl3þDMSO-d6) d: 13.64, 21.32, 29.59, 62.22, 63.36,
126.17, 126.84, 127.01, 128.54, 129.22, 129.26, 129.33, 129.41, 129.78,
132.96, 137.92, 143.24, 167.47, 197.89. MS (ESI-TOF) m/z: 376.12
(Mþ1). HPLC analysis not carried out.
4.3.9. Ethyl 2-(4-methylphenylsulfonamido)-2-(naphthalen-1-yl)ac-
etate (3g). Yellow solid (79% yield). 1H NMR (400 MHz,
CDCl3þDMSO-d6) d: 1.15 (m, CH3, 3H), 2.31 (s, CH3Ts, 3H),
3.98e4.25 (m, CH2, 2H), 5.74 (s, CH, 1H), 5.81 (s, NH, 1H), 7.48e7.53
(Ar, 2H), 7.57e7.61 (Ar, 4H), 7.91e7.98 (Ar, 2H), 8.11e8.18 (Ar, 2H),
8.35e8.41 (Ar, 1H). 13C NMR (100 MHz, CDCl3þDMSO-d6) d: 14.13,
21.67, 57.25, 62.63, 125.16, 125.30, 125.95, 126.60, 127.01, 127.28,
128.05,128.96,129.85,130.96,132.55,133.55,137.76,139.20,143.75,
149.27, 157.94. MS (ESI-TOF) m/z: 384.14 (Mþ1). HPLC analysis not
carried out.
4.3.10. Ethyl 2-(4-ﬂuorophenyl)-2-(4-methylphenylsulfonamido)ace-
tate (3h).35 White solid (45% yield). 1H NMR (400 MHz,
CDCl3þDMSO-d6) d: 0.92e0.97 (m, CH3, 3H), 2.31 (s, CH3Ts, 3H),
3.77e3.93 (m, CH2, 2H), 5.12e5.17 (d, CH, 1H), 6.03 (s, NH, 1H),
7.13e7.19 (Ar, 4H), 7.39e7.53 (Ar, 1H), 7.57e7.59 (Ar, 2H), 7.69e7.72
(Ar, 1H). 13C NMR (100 MHz, CDCl3þDMSO-d6) d: 13.60, 21.33,
63.00, 66.81, 115.26, 115.42, 125.71, 126.92, 128.20, 128.72, 129.09,
137.08, 137.86, 138.08, 140.34, 142.94, 167.23. MS (ESI-TOF) m/z:
352.11 (Mþ1). HPLC analysis not carried out.
4.3.11. Ethyl 2-(3-(benzyloxy)phenyl)-2-(4-methylphenylsulfona
mido)acetate (3i). Colourless oil (30% yield). 1H NMR (400 MHz,
CDCl3) d: 1.10 (dd, CH3, 3H), 2.36 (s, CH3Ts, 3H), 3.94e4.07 (m, CH2,
2H), 4.95e4.96 (d, CH2, 1H), 5.07 (d, CH2, 1H), 5.12e5.14 (d, CH, 1H),
5.74e5.76 (d, NH, 1H), 6.83e6.88 (Ar, 2H), 7.18e7.20 (Ar, 2H),
7.33e7.45 (Ar, 7H), 7.62e7.64 (Ar, 2H). 13C NMR (100 MHz, CDCl3) d:
14.06, 22.66, 59.33, 62.36, 69.43, 113.02, 113.30, 115.07, 115.25,
119.34, 119.86, 127.34, 127.60, 128.64, 128.19, 128.73, 129.58, 136.64,
137.15, 140.12, 143.61, 159.11, 173.70. MS (ESI-TOF) m/z: 440.17
(Mþ1). HPLC analysis not carried out.
4.3.12. Ethyl 2-(3-hydroxyphenyl)-2-(4-methylphenylsulfonamido)
acetate (3j). White solid (31% yield). 1H NMR (400 MHz,
CDCl3þDMSO-d6) d: 0.97 (dd, CH3, 3H), 2.33 (s, CH3Ts, 3H), 3.63 (s,
OH, 1H), 3.81e3.93 (m, CH2, 2H), 5.17e5.19 (d, CH, 1H), 5.87 (s, NH,
1H), 6.77e6.79 (Ar, 2H), 7.10e7.21 (Ar, 4H), 7.60e7.63 (Ar, 2H). 13C
NMR (100 MHz, CDCl3þDMSO-d6) d: 13.62, 21.07, 63.37, 66.55,
115.45, 119.39, 126.16, 127.00, 128.36, 129.33, 129.35, 129.44, 137.86,
140.20, 143.29, 156.94, 167.34. MS (ESI-TOF) m/z: 350.11 (Mþ1).
HPLC analysis not carried out.
4.3.13. Ethyl 2-(3-aminophenyl)-2-(4-methylphenylsulfonamido)ac-
etate (3k). Orange solid (37% yield). 1H NMR (400 MHz, CDCl3) d:
0.88 (m, CH3, 3H), 2.43 (s, CH3Ts, 3H), 4.09e4.25 (m, CH2þNH2, 4H),
4.89e4.91 (d, CH, 1H), 6.17 (s, Ar, 1H), 6.21e6.27 (d, NH, 1H),
6.96e7.01 (Ar, 2H), 7.29e7.36 (Ar, 2H), 7.79e7.83 (Ar, 2H). 13C NMR
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(100 MHz, CDCl3) d: 14.26, 21.65, 61.02, 62.03, 114.09, 114.39, 117.88,
126.59, 129.69, 130.33, 137.45, 137.25, 139.25, 143.75, 145.56, 172.15.
MS (ESI-TOF) m/z: 287.15. HPLC analysis not carried out.
4.3.14. Ethyl 2-(4-methoxyphenyl)-2-(4-methylphenylsulfonamido)
acetate (3l). White solid (39% yield). 1H NMR (400 MHz, CDCl3) d:
1.09 (t, CH3, 3H), 2.38 (s, CH3Ts, 3H), 3.76 (s, OCH3, 3H), 3.89e4.05
(m, CH2, 2H), 4.97e4.99 (d, CH, 1H), 5.71e5.73 (d, NH, 1H),
6.75e6.78 (Ar, 2H), 6.88e6.90 (Ar, 1H), 7.12e7.21 (Ar, 3H), 7.32 (Ar,
1H), 7.62e7.64 (Ar, 1H). 13C NMR (100 MHz, CDCl3) d: 14.38, 22.98,
55.45, 58.73, 62.04, 114.11, 114.25, 114.90, 126.58, 127.34, 127.61,
127.96, 128.48, 129.58, 130.77, 143.66, 159.62, 170.54. MS (ESI-TOF)
m/z: 386.11 (Mþ1þNa). HPLC analysis was not carried out.
4.4. Synthesis of (rac)-a-phenylglycine (11)
Ethyl 2-(4-methylphenylsulfonamido)-2-phenylacetate (3a)
(92.3 mg, 0.3 mmol) in THF (5 ml) was stirred with an aqueous
solution of NaOH (2 M) (1.0 ml, 1.5 mmol) at 50 C and monitored
by TLC. THF was evaporated under reduced pressure and the mix-
ture extracted with CH2Cl2 (510 ml). The aqueous phase was
evaporated under reduced pressure and the desired a-phenyl-
glycine (11) was obtained as a white solid (>90% yield). Mp:
>300 C. 1H NMR (400 MHz, D2O) d: 4.47 (s, CH, 1H), 7.18e7.19 (m,
Ar, 5H). 13C NMR (100 MHz, D2O) d: 65.63, 126.35, 126.58, 127.50,
128.17, 128.96, 140.86, 181.51. MS (ESI-TOF) m/z: 158.97 (Mþ).
4.5. General procedure for the one-pot arylationeamine de-
protection to afford a-amino ester (12)
1,4-Dioxane (1.0 ml) was added to a round-bottom ﬂask con-
taining [Rh(COD)OH]2 (5 mol %) and (R,R)-DeguPhos (5.5 mol %)
and left stirring at room temperature 30 min. 2,2-Bis(4-
methylphenylsulfonamido)acetate (2) (0.19 mmol), phenylboronic
acid (0.38 mmol), 3 A MS (200 mg) and 1,4-dioxane (3 ml) were
added to the reaction vessel sequentially, followed by NEt3
(0.29mmol) and K2CO3 (1.14mmol). The reactionwas left stirring at
70 C for 2 days. After cooling to room temperature, the crude
mixturewas ﬁltered over Celite in a sintered glass ﬁlter andwashed
with AcOEt. The solvent was evaporated under reduced pressure
and the crude product puriﬁed by column chromatography (SiO2
gel, hex/AcOEt (5:1)) providing the deprotected amine product (12)
as a yellow oil (72% yield). 1H NMR (400 MHz, CDCl3) d: 1.22 (t,
J¼8 Hz, CH3, 3H), 1.26 (s, NH2, 1H), 2.42 (s, NH2, 1H), 4.12e4.28 (m,
CH2, 2H), 5.16 (s, CH, 1H), 7.28e7.38 (m, Ar, 2H), 7.41e7.43 (m, Ar,
2H), 7.79e7.81 (d, Ar, 1H). 13C NMR (100MHz, CDCl3) d: 14.13, 62.37,
73.01, 126.55, 128.53, 128.69, 129.81, 138.51, 143.65, 173.81. MS (ESI-
TOF) m/z: 203.07 (Mþ1). HPLC analysis not carried out.
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